Related Experiment Video
Updated: Apr 22, 2026
13:36
Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches
Published on: May 6, 2015
10.0K
Novel vaccine vectors for HIV-1
Dan H Barouch1, Louis J Picker2
1Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA, and the Ragon Institute of MGH, MIT and Harvard, Cambridge, Massachusetts 02139, USA.
Nature Reviews. Microbiology
|October 9, 2014
Summary
Developing novel vaccine vectors is crucial for combating the global human immunodeficiency virus type 1 (HIV-1) epidemic. Adenovirus and cytomegalovirus vectors show promise, offering distinct immunological strategies for potential HIV-1 vaccine development.
Area of Science:
- Immunology
- Vaccinology
- Virology
Background:
- The global human immunodeficiency virus type 1 (HIV-1) epidemic necessitates a safe and effective vaccine.
- Previous vaccine platform trials have yielded disappointing clinical efficacy results, highlighting the need for novel approaches.
Approach:
- This opinion article explores the scientific basis and clinical potential of adenovirus and cytomegalovirus (CMV) vaccine vectors for HIV-1.
- These represent contrasting yet potentially complementary vector strategies.
Key Points:
- Both adenovirus and cytomegalovirus vector platforms have shown partial protection against simian immunodeficiency virus (SIV) challenges in preclinical models.
- These vector platforms utilize different immunological mechanisms to achieve protection.
Conclusions:
- Novel adenovirus and cytomegalovirus vaccine vectors offer promising avenues for future HIV-1 vaccine development.
- Further research into these distinct vector approaches may be essential for advancing HIV-1 vaccine strategies.
